| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sabela Lens, Jose L Calleja, Ana Campillo, Jose A Carrión, Teresa Broquetas, Christie Perello, Juan de la Revilla, Zoe Mariño, María-Carlota Londoño, Jose M Sánchez-Tapias, Álvaro Urbano-Ispizua and Xavier Forns |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Instituto de Salud Carlos III |
PI11/01907(in part) |
| Ministerio de Economía y Competitividad, co-funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa |
|
| Roche Organ Transplantation Research Foundation |
442035057(to Forns X) |
|
| Corresponding Author |
Sabela Lens, MD, Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, C/Villarroel 170, 08036 Barcelona, Spain. slens@clinic.ub.es |
| Key Words |
Aplastic anemia; Hepatitis C; Telaprevir; Interferon; Protease inhibitors |
| Core Tip |
Addition of the new directly acting antivirals, Telaprevir and Boceprevir, clearly improved sustained virological response rates in patients with chronic hepatitis C. However, these combinations have also increased the risk of serious adverse events, especially in patients with advanced liver fibrosis. We describe the development of severe pancytopenia and aplastic anemia during triple therapy with telaprevir in patients with advanced liver disease (before or after liver transplantation). Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications. |
| Publish Date |
2015-05-13 10:38 |
| Citation |
Lens S, Calleja JL, Campillo A, Carrión JA, Broquetas T, Perello C, de la Revilla J, Mariño Z, Londoño MC, Sánchez-Tapias JM, Urbano-Ispizua Á, Forns X. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World J Gastroenterol 2015; 21(17): 5421-5426 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i17/5421.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i17.5421 |
